Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | OPRD1 | P41143 | 14/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL219432 | 0.85 | MEN1 (1.00) | MEN1KMT2AOPRD1CYP2D6CYP19A1 | |
| SCHEMBL2794662 | 0.85 | MEN1 (1.00) | MEN1KMT2AOPRD1CYP2D6CYP19A1 | |
| SCHEMBL27984478 | 0.84 | MEN1 (0.72) | MEN1KMT2AOPRD1CYP2D6CYP19A1 | |
| Fluoride SCHEMBL27959930 | 0.83 | MEN1 (0.96) | MEN1KMT2AOPRD1CYP2D6CYP19A1 | |
| Piperazine SCHEMBL28229145 | 0.83 | MEN1 (0.96) | MEN1KMT2AOPRD1CYP2D6CYP19A1 | |
| Hydrochloric Acid SCHEMBL7006476 | 0.83 | MEN1 (0.96) | MEN1KMT2AOPRD1CYP2D6CYP19A1 | |
| SCHEMBL27485345 | 0.83 | MEN1 (0.96) | MEN1KMT2AOPRD1CYP2D6CYP19A1 | |
| Hydrochloric Acid SCHEMBL11456225 | 0.83 | MEN1 (0.96) | MEN1KMT2AOPRD1CYP2D6CYP19A1 | |
| SCHEMBL1138320 | 0.82 | MEN1 (0.79) | MEN1KMT2AOPRD1CYP2D6CYP19A1 | |
| SCHEMBL1138318 | 0.82 | MEN1 (0.79) | MEN1KMT2AOPRD1CYP2D6CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306087-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306087-A1 | Therapeutic Agents | NLN, BDNF, GAP43 | MEN1 2783/4885KMT2A 3556/4885OPRD1 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.